ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.
Authors
Joshua J. Meeks (ORCID: https://orcid.org/0000-0002-5444-5510)
Girish S. Kulkarni (ORCID: https://orcid.org/0000-0002-6929-6124)
ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.
Joshua J. Meeks, Girish S. Kulkarni, Wassim Kassouf, Jørn S. Jakobsen et al.
Citations
1 citations
Journal
Journal of Clinical Oncology
Topics
Cancer Treatment and Pharmacology
Field-Weighted Citation Impact (FWCI)
1.05
article
ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.
Joshua J. Meeks, Girish S. Kulkarni, Wassim Kassouf, Jørn S. Jakobsen, Yair Lotan, Siamak Daneshmand, Peter Albers, Trinity J. Bivalacqua, Stephen A. Boorjian, Kristian Vinter Juul, Paolo Gontero
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(5_suppl)
Institutions
Northwestern University (US), University of Southern California (US), University Health Network (CA), Mayo Clinic (US), Hospital of the University of Pennsylvania (US), McGill University Health Centre (CA), Princess Margaret Cancer Centre (CA), Düsseldorf University Hospital (DE), Southwestern Medical Center (US), Ferring Pharmaceuticals (Denmark) (DK), Southwestern Medical Center (US), Heinrich Heine University Düsseldorf (DE), University of Turin (IT), The University of Texas Southwestern Medical Center (US)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study. — Joshua J. Meeks, Girish S. Kulkarni, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS